For primary hyperlipidemia. ANDA 204893, held by Macleods Pharms. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 204893 (Colesevelam Hydrochloride), held by Macleods Pharms, was first approved by FDA on Apr 18, 2025, with 0 approved supplements and 0 published complete response letters.
Colesevelam hydrochloride tablets are a bile acid sequestrant indicated as an adjunct to diet and exercise to:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 18, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters